Figure 1‑1: Orthopedic Biomaterials Market Share Ranking by Segment, Europe, 2023 |
Figure 1‑2: Companies Researched in This Report |
Figure 1‑3: Factors Impacting the Orthopedic Biomaterials Market by Segment, Europe (1 of 2) |
Figure 1‑4: Factors Impacting the Orthopedic Biomaterials Market by Segment, Europe (2 of 2) |
Figure 1‑5: Recent Events in the Orthopedic Biomaterials Market, Europe, 2021 – 2024 (1 of 7) |
Figure 1‑6: Recent Events in the Orthopedic Biomaterials Market, Europe, 2021 – 2024 (2 of 7) |
Figure 1‑7: Recent Events in the Orthopedic Biomaterials Market, Europe, 2021 – 2024 (3 of 7) |
Figure 1‑8: Recent Events in the Orthopedic Biomaterials Market, Europe, 2021 – 2024 (4 of 7) |
Figure 1‑9: Recent Events in the Orthopedic Biomaterials Market, Europe, 2021 – 2024 (5 of 7) |
Figure 1‑10: Recent Events in the Orthopedic Biomaterials Market, Europe, 2021 – 2024 (6 of 7) |
Figure 1‑11: Recent Events in the Orthopedic Biomaterials Market, Europe, 2021 – 2024 (7 of 7) |
Figure 1‑12: Orthopedic Biomaterials Market Segmentation, Europe (1 of 2) |
Figure 1‑13: Orthopedic Biomaterials Market Segmentation, Europe (2 of 2) |
Figure 1‑14: Orthopedic Biomaterials Procedure Segmentation, Europe (1 of 3) |
Figure 1‑15: Orthopedic Biomaterials Procedure Segmentation, Europe (2 of 3) |
Figure 1‑16: Orthopedic Biomaterials Procedure Segmentation, Europe (3 of 3) |
Figure 1‑17: Key Report Updates (1 of 2) |
Figure 1‑18: Version History |
Figure 2‑1: Orthopedic Biomaterials Market by Segment, Worst Case Scenario, Europe, 2020 – 2030 (€M) |
Figure 2‑2: Orthopedic Biomaterials Market by Segment, Base Case Scenario, Europe, 2020 – 2030 (€M) |
Figure 2‑3: Orthopedic Biomaterials Market by Segment, Best Case Scenario, Europe, 2020 – 2030 (€M) |
Figure 3‑1: Bone Graft Substitutes Products by Company (1 of 4) |
Figure 3‑2: Bone Graft Substitutes Products by Company (2 of 4) |
Figure 3‑3: Bone Graft Substitutes Products by Company (3 of 4) |
Figure 3‑4: Bone Graft Substitutes Products by Company (4 of 4) |
Figure 3‑5: Growth Factor Products by Company |
Figure 3‑6: Cell Therapy Products by Company |
Figure 3‑7: Hyaluronic Acid Viscosupplementation by Products by Company |
Figure 3‑8: Cartilage Repair Products by Company |
Figure 3‑9: Class 2 Device Recall GRAFTON DBM (Gel, Flex, Putty, Matrix, Crunch) |
Figure 3‑10: Class 2 Device Recall GRAFTON PLUS DBM Paste |
Figure 3‑11: Class 2 Device Recall Magnifuse Bone Graft |
Figure 3‑12: Class 2 Device Recall Grafton DBF Inject |
Figure 3‑13: Class 2 Device Recall OsteoSelect Demineralized Bone Matrix (DBM) Putty |
Figure 3‑14: Class 2 Device Recall PROSTIM 10cc INJECTABLE |
Figure 3‑15: Class 2 Device Recall Opteform Allograft Disc |
Figure 3‑16: Class 2 Device Recall Bioactive Bone Graft Putty |
Figure 3‑17: Class 3 Device Recall iFACTOR Peptide Enhanced Bone Graft Putty |
Figure 3‑18: ACDF Using Structural Allograft vs. Tritanium C |
Figure 3‑19: Clinical Study of Bone Graft Substitutes in Orthopaedic and Spinal Applications |
Figure 3‑20: OSTEOAMP Lumbar Fusion Intra-Patient Controlled Study |
Figure 3‑21: Rate of Bony Fusion Using NanoBone® Synthetic Bone Graft Versus Local Autologous Bone Graft. (BONE) |
Figure 3‑22: Demineralized Bone Matrix Rotator Cuff Study |
Figure 3‑23: Clinical Outcomes Associated with the Use of ViviGen® for the Treatment of Lumbar Degenerative Disc Disease |
Figure 3‑24: The Effect of Bone-void Filler on Anterior Knee Pain Following ACL Reconstruction |
Figure 3‑25: Long-term Safety and Effectiveness of AUGMENT® Injectable Bone Graft Compared to Autologous Bone Graft |
Figure 3‑26: Transforaminal Lumbar Interbody Fusion (TLIF) |
Figure 3‑27: A Post Market Surveillance on INFUSE Bone Graft |
Figure 3‑28: Long-term Safety and Effectiveness of AUGMENT® Injectable Bone Graft Compared to Autologous Bone Graft |
Figure 3‑29: Evaluation of the Effectiveness of AMPLEX® Compared to Autogenous Bone Grafts |
Figure 3‑30: Effect of PRP, PPP, & BMAC on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies |
Figure 3‑31: Bone Marrow Aspirate Concentrate (BMAC) vs Corticosteroid Injection |
Figure 3‑32: BMAC & Allograft vs BMP-2 |
Figure 3‑33: Bone Marrow Aspirate Concentrate (BMAC)Treatment for Knee Osteoarthritis (BMAC) |
Figure 3‑34: Platelet Rich Plasma in Knee Osteoarthritis |
Figure 3‑35: Platelet-Rich Plasma (PRP) for Treatment of Symptomatic Lumbar Facet Syndrome of the Spine |
Figure 3‑36: A Prospective Study of Clinical Outcomes Following a Single Intradiscal Injection of Bone Marrow Aspirate Concentrate (BMAC) for Single Level Discogenic Low Back Pain |
Figure 3‑37: ArtiAid® for Knee Osteoarthritis: A Post-market Study |
Figure 3‑38: The Effectiveness of Different Doses of Hyaluronic Acid Injections in Knee Osteoarthritis |
Figure 3‑39: Euflexxa for the Treatment of Osteoarthritis |
Figure 3‑40: MONOVISC for Ankle Joint Pain Relief |
Figure 3‑41: MONOVISC for Shoulder Joint Pain Relief |
Figure 3‑42: MONOVISC for Hip Joint Pain Relief |
Figure 3‑43: Comparison of Hyaluronic Acid and Platelet-Rich Plasma Injections |
Figure 3‑44: Prospective Evaluation of ProChondrix CR for Repair of Articular Cartilage Defects on Femoral Condyle and Patella |
Figure 3‑45: Osteochondral Allograft in the Surgical Treatment of Basal Joint Arthritis |
Figure 3‑46: Phase 2 Clinical Trial of CartiLife® in the United States |
Figure 3‑47: A Study to Evaluate the Efficacy of BioCartilage® Micronized Cartilage Matrix in Microfracture Treatment of Osteochondral Defects |
Figure 4‑1: Currency Exchange Rate, 2023 |
Figure 4‑2: Orthopedic Biomaterials Market by Segment, Europe, 2020 – 2030 (€M) |
Figure 4‑3: Orthopedic Biomaterials Market by Segment, Europe, 2020 – 2030 (US$M) |
Figure 4‑4: Leading Competitors, Orthopedic Biomaterials Market, Europe, 2023 (1 of 2) |
Figure 4‑5: Leading Competitors, Orthopedic Biomaterials Market, Europe, 2023 (2 of 2) |
Figure 4‑6: SWOT Analysis, Arthrex |
Figure 4‑7: SWOT Analysis, Biocomposites |
Figure 4‑8: SWOT Analysis, Bioventus |
Figure 4‑9: SWOT Analysis, DePuy Synthes |
Figure 4‑10: SWOT Analysis, Ferring Pharmaceuticals |
Figure 4‑11: SWOT Analysis, Isto Biologics |
Figure 4‑12: SWOT Analysis, Medtronic |
Figure 4‑13: SWOT Analysis, MTF |
Figure 4‑14: SWOT Analysis, NuVasive |
Figure 4‑15: SWOT Analysis, Orthofix |
Figure 4‑16: SWOT Analysis, Sanofi |
Figure 4‑17: SWOT Analysis, Stryker |
Figure 4‑18: SWOT Analysis, Terumo |
Figure 4‑19: SWOT Analysis, Vericel |
Figure 4‑20: SWOT Analysis, Zimmer Biomet |
Figure 6‑1: Orthopedic Biomaterials Procedures by Segment, Europe, 2020 – 2030 |
Figure 6‑2: Orthopedic Biomaterials Procedures by Segment, Europe, 2020 – 2030 |
Figure 6‑3: Orthopedic Bone Grafting Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑4: Orthopedic Bone Grafting Procedures by Material, Europe, 2020 – 2030 |
Figure 6‑5: Orthopedic Bone Grafting Procedures by Indication, Europe, 2020 – 2030 (1 of 2) |
Figure 6‑6: Orthopedic Bone Grafting Procedures by Indication, Europe, 2020 – 2030 (2 of 2) |
Figure 6‑7: Cervical Spine Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑8: Thoracolumbar Spine Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑9: Non-Union Trauma Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑10: Fresh Fracture Trauma Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑11: Hip Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑12: Knee Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑13: Foot Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑14: Craniomaxillofacial Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑15: Oncology Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑16: Average Units Used per Procedure by Indication, Europe, 2020 – 2030 |
Figure 6‑17: Allograft Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑18: Allograft Procedures by Indication, Europe, 2020 – 2030 (1 of 2) |
Figure 6‑19: Allograft Procedures by Indication, Europe, 2020 – 2030 (2 of 2) |
Figure 6‑20: Allograft Cervical Spine Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑21: Allograft Thoracolumbar Spine Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑22: Allograft Non-Union Trauma Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑23: Allograft Fresh Fracture Trauma Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑24: Allograft Hip Large Joint Reconstruction Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑25: Allograft Knee Large Joint Reconstruction Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑26: Allograft Foot Reconstruction Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑27: Allograft Craniomaxillofacial Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑28: Allograft Oncology Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑29: DBM Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑30: DBM Procedures by Indication, Europe, 2020 – 2030 |
Figure 6‑31: DBM Cervical Spine Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑32: DBM Thoracolumbar Spine Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑33: DBM Non-Union Trauma Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑34: DBM Fresh Fracture Trauma Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑35: DBM Craniomaxillofacial Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑36: Synthetic Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑37: Synthetic Procedures by Indication, Europe, 2020 – 2030 (1 of 2) |
Figure 6‑38: Synthetic Procedures by Indication, Europe, 2020 – 2030 (2 of 2) |
Figure 6‑39: Synthetic Cervical Spine Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑40: Synthetic Thoracolumbar Spine Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑41: Synthetic Non-Union Trauma Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑42: Synthetic Fresh Fracture Trauma Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑43: Synthetic Hip Large Joint Reconstruction Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑44: Synthetic Knee Large Joint Reconstruction Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑45: Synthetic Foot Reconstruction Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑46: Synthetic Craniomaxillofacial Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑47: Synthetic Oncology Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑48: Orthopedic Bone Grafting Procedures by Care Setting, Europe, 2020 – 2030 |
Figure 6‑49: Orthopedic Growth Factor Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑50: Orthopedic Growth Factor Procedures by Indication, Europe, 2020 – 2030 |
Figure 6‑51: Spine Growth Factor Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑52: Tibial Growth Factor Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑53: Orthopedic Growth Factor Procedures by Care Setting, Europe, 2020 – 2030 |
Figure 6‑54: Orthopedic Cell Therapy Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑55: Orthopedic Cell Therapy Procedures by Material Type, Europe, 2020 – 2030 |
Figure 6‑56: Platelet-Rich Plasma Procedures by Country, Europe, 2020 – 2030 |
Figure 6‑57: Bone Marrow Aspirate Concentrate Procedures by Indication, Europe, 2020 – 2030 |
Figure 6‑58: Orthopedic Cell Therapy Procedures by Care Setting, Europe, 2020 – 2030 |
Figure 6‑59: Hyaluronic Acid Viscosupplementation Total Injections by Country, Europe, 2020 – 2030 |
Figure 6‑60: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, Europe, 2020 – 2030 (1 of 2) |
Figure 6‑61: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, Europe, 2020 – 2030 (2 of 2) |
Figure 6‑62: Single-Injection Cycles by Country, Europe, 2020 – 2030 |
Figure 6‑63: Two-Injection Cycles by Country, Europe, 2020 – 2030 |
Figure 6‑64: Three-Injection Cycles by Country, Europe, 2020 – 2030 |
Figure 6‑65: Five-Injection Cycles by Country, Europe, 2020 – 2030 |
Figure 6‑66: Hyaluronic Acid Viscosupplementation Procedures by Care Setting, Europe, 2020 – 2030 |
Figure 6‑67: Orthopedic Cartilage Repair Procedures by Type, Europe, 2020 – 2030 |
Figure 6‑68: Orthopedic Cartilage Repair Procedures by Care Setting, Europe, 2020 – 2030 |
Figure 7‑1: Bone Graft Substitute Market by Segment, Europe, 2020 – 2030 (€M) |
Figure 7‑2: Bone Graft Substitute Market by Segment, Europe, 2020 – 2030 (US$M) |
Figure 7‑3: Total Bone Graft Substitute Market, Europe, 2020 – 2030 |
Figure 7‑4: Units Sold by Country, Total Bone Graft Substitute Market, Europe, 2020 – 2030 |
Figure 7‑5: Average Selling Price by Country, Total Bone Graft Substitute Market, Europe, 2020 – 2030 (€) |
Figure 7‑6: Average Selling Price by Country, Total Bone Graft Substitute Market, Europe, 2020 – 2030 (US$) |
Figure 7‑7: Market Value by Country, Total Bone Graft Substitute Market, Europe, 2020 – 2030 (€M) |
Figure 7‑8: Market Value by Country, Total Bone Graft Substitute Market, Europe, 2020 – 2030 (US$M) |
Figure 7‑9: Allograft Market, Europe, 2020 – 2030 |
Figure 7‑10: Units Sold by Country, Allograft Market, Europe, 2020 – 2030 |
Figure 7‑11: Average Selling Price by Country, Allograft Market, Europe, 2020 – 2030 (€) |
Figure 7‑12: Average Selling Price by Country, Allograft Market, Europe, 2020 – 2030 (US$) |
Figure 7‑13: Market Value by Country, Allograft Market, Europe, 2020 – 2030 (€M) |
Figure 7‑14: Market Value by Country, Allograft Market, Europe, 2020 – 2030 (US$M) |
Figure 7‑15: Demineralized Bone Matrix Market, Europe, 2020 – 2030 |
Figure 7‑16: Units Sold by Country, Demineralized Bone Matrix Market, Europe, 2020 – 2030 |
Figure 7‑17: Average Selling Price by Country, Demineralized Bone Matrix Market, Europe, 2020 – 2030 (€) |
Figure 7‑18: Average Selling Price by Country, Total Demineralized Bone Matrix Market, Europe, 2020 – 2030 (US$) |
Figure 7‑19: Market Value by Country, Total Demineralized Bone Matrix Market, Europe, 2020 – 2030 (€M) |
Figure 7‑20: Market Value by Country, Total Demineralized Bone Matrix Market, Europe, 2020 – 2030 (US$M) |
Figure 7‑21: Synthetic Market, Europe, 2020 – 2030 |
Figure 7‑22: Units Sold by Country, Synthetic Market, Europe, 2020 – 2030 |
Figure 7‑23: Average Selling Price by Country, Total Synthetic Market, Europe, 2020 – 2030 (€) |
Figure 7‑24: Average Selling Price by Country, Total Synthetic Market, Europe, 2020 – 2030 (US$) |
Figure 7‑25: Market Value by Country, Total Synthetic Market, Europe, 2020 – 2030 (€M) |
Figure 7‑26: Market Value by Country, Total Synthetic Market, Europe, 2020 – 2030 (US$M) |
Figure 7‑27: Total Bone Graft Substitute Units Sold by Indication, Europe, 2020 – 2030 (1 of 2) |
Figure 7‑28: Total Bone Graft Substitute Units Sold by Indication, Europe, 2020 – 2030 (2 of 2) |
Figure 7‑29: Allograft Bone Graft Substitute Units Sold by Indication, Europe, 2020 – 2030 |
Figure 7‑30: Spine Allograft Bone Graft Substitute Units Sold by Indication, Europe, 2020 – 2030 |
Figure 7‑31: Units Sold by Country, Cervical Spine Allograft Bone Graft Substitute, Europe, 2020 – 2030 |
Figure 7‑32: Units Sold by Country, Thoracolumbar Spine Allograft Bone Graft Substitute, Europe, 2020 – 2030 |
Figure 7‑33: Trauma Allograft Bone Graft Substitute Units Sold by Indication, Europe, 2020 – 2030 |
Figure 7‑34: Units Sold by Country, Non-Union Trauma Allograft Bone Graft Substitute, Europe, 2020 – 2030 |
Figure 7‑35: Units Sold by Country, Fresh Fracture Trauma Allograft Bone Graft Substitute, Europe, 2020 – 2030 |
Figure 7‑36: Large Joint Reconstruction Allograft Bone Graft Substitute Units Sold by Anatomy, Europe, 2020 – 2030 |
Figure 7‑37: Units Sold by Country, Hip Large Joint Reconstruction Allograft Bone Graft Substitute, Europe, 2020 – 2030 |
Figure 7‑38: Units Sold by Country, Knee Large Joint Reconstruction Allograft Bone Graft Substitute, Europe, 2020 – 2030 |
Figure 7‑39: Units Sold by Country, Foot Reconstruction Allograft Bone Graft Substitute, Europe, 2020 – 2030 |
Figure 7‑40: Units Sold by Country, Craniomaxillofacial Allograft Bone Graft Substitute, Europe, 2020 – 2030 |
Figure 7‑41: Units Sold by Country, Oncology Allograft Bone Graft Substitute, Europe, 2020 – 2030 |
Figure 7‑42: Demineralized Bone Matrix Allograft Units Sold by Indication, Europe, 2020 – 2030 |
Figure 7‑43: Spine Demineralized Bone Matrix Allograft Units Sold by Anatomy, Europe, 2020 – 2030 |
Figure 7‑44: Units Sold by Country, Cervical Spine Demineralized Bone Matrix Allograft, Europe, 2020 – 2030 |
Figure 7‑45: Units Sold by Country, Thoracolumbar Spine Demineralized Bone Matrix Allograft, Europe, 2020 – 2030 |
Figure 7‑46: Trauma Demineralized Bone Matrix Allograft Units Sold by Anatomy, Europe, 2020 – 2030 |
Figure 7‑47: Units Sold by Country, Non-Union Trauma Demineralized Bone Matrix Allograft, Europe, 2020 – 2030 |
Figure 7‑48: Units Sold by Country, Fresh Fracture Trauma Demineralized Bone Matrix Allograft, Europe, 2020 – 2030 |
Figure 7‑49: Units Sold by Country, Craniomaxillofacial Demineralized Bone Matrix Allograft, Europe, 2020 – 2030 |
Figure 7‑50: Synthetic Bone Graft Substitute Units Sold by Indication, Europe, 2020 – 2030 |
Figure 7‑51: Spine Synthetic Bone Graft Substitute Units Sold by Anatomy, Europe, 2020 – 2030 |
Figure 7‑52: Units Sold by Country, Cervical Spine Synthetic Bone Graft Substitute, Europe, 2020 – 2030 |
Figure 7‑53: Units Sold by Country, Thoracolumbar Spine Synthetic Bone Graft Substitute, Europe, 2020 – 2030 |
Figure 7‑54: Trauma Synthetic Bone Graft Substitute Units Sold by Indication, Europe, 2020 – 2030 |
Figure 7‑55: Units Sold by Country, Non-Union Trauma Synthetic Bone Graft Substitute, Europe, 2020 – 2030 |
Figure 7‑56: Units Sold by Country, Fresh Fracture Trauma Synthetic Bone Graft Substitute, Europe, 2020 – 2030 |
Figure 7‑57: Large Joint Reconstruction Synthetic Bone Graft Substitute Units Sold by Anatomy, Europe, 2020 – 2030 |
Figure 7‑58: Units Sold by Country, Hip Large Joint Reconstruction Synthetic Bone Graft Substitute, Europe, 2020 – 2030 |
Figure 7‑59: Units Sold by Country, Knee Large Joint Reconstruction Synthetic Bone Graft Substitute, Europe, 2020 – 2030 |
Figure 7‑60: Units Sold by Country, Foot Reconstruction Synthetic Bone Graft Substitute, Europe, 2020 – 2030 |
Figure 7‑61: Units Sold by Country, Craniomaxillofacial Synthetic Bone Graft Substitute, Europe, 2020 – 2030 |
Figure 7‑62: Units Sold by Country, Oncology Synthetic Bone Graft Substitute, Europe, 2020 – 2030 |
Figure 7‑63: Units Sold by Country, Generation 1 Synthetic Bone Graft Substitute, Europe, 2020 – 2030 |
Figure 7‑64: Units Sold by Country, Generation 2 Synthetic Bone Graft Substitute, Europe, 2020 – 2030 |
Figure 7‑65: Leading Competitors by Country, Orthopedic Bone Graft Substitute Market, Europe, 2023 |
Figure 7‑66: Leading Competitors by Segment, Orthopedic Bone Graft Substitute Market, Europe, 2023 |
Figure 8‑1: Orthopedic Growth Factor Market by Segment, Europe, 2020 – 2030 (€M) |
Figure 8‑2: Orthopedic Growth Factor Market by Segment, Europe, 2020 – 2030 (US$M) |
Figure 8‑3: Orthopedic Growth Factor Market, Europe, 2020 – 2030 |
Figure 8‑4: Units Sold (5 cc) by Country, Orthopedic Growth Factor Market, Europe, 2020 – 2030 |
Figure 8‑5: Average Selling Price by Country, Orthopedic Growth Factor Market, Europe, 2020 – 2030 (€) |
Figure 8‑6: Average Selling Price by Country, Orthopedic Growth Factor Market, Europe, 2020 – 2030 (US$) |
Figure 8‑7: Market Value by Country, Orthopedic Growth Factor Market, Europe, 2020 – 2030 (€M) |
Figure 8‑8: Market Value by Country, Orthopedic Growth Factor Market, Europe, 2020 – 2030 (US$M) |
Figure 8‑9: Spine Orthopedic Growth Factor Market, Europe, 2020 – 2030 |
Figure 8‑10: Units Sold (5 cc) by Country, Spine Orthopedic Growth Factor Market, Europe, 2020 – 2030 |
Figure 8‑11: Average Selling Price by Country, Spine Orthopedic Growth Factor Market, Europe, 2020 – 2030 (€) |
Figure 8‑12: Average Selling Price by Country, Spine Orthopedic Growth Factor Market, Europe, 2020 – 2030 (US$) |
Figure 8‑13: Market Value by Country, Spine Orthopedic Growth Factor Market, Europe, 2020 – 2030 (€M) |
Figure 8‑14: Market Value by Country, Spine Orthopedic Growth Factor Market, Europe, 2020 – 2030 (US$M) |
Figure 8‑15: Tibial Orthopedic Growth Factor Market, Europe, 2020 – 2030 |
Figure 8‑16: Units Sold (5 cc) by Country, Tibial Orthopedic Growth Factor Market, Europe, 2020 – 2030 |
Figure 8‑17: Average Selling Price by Country, Tibial Orthopedic Growth Factor Market, Europe, 2020 – 2030 (€) |
Figure 8‑18: Average Selling Price by Country, Tibial Orthopedic Growth Factor Market, Europe, 2020 – 2030 (US$) |
Figure 8‑19: Market Value by Country, Tibial Orthopedic Growth Factor Market, Europe, 2020 – 2030 (€M) |
Figure 8‑20: Market Value by Country, Tibial Orthopedic Growth Factor Market, Europe, 2020 – 2030 (US$M) |
Figure 8‑21: Units Sold (5 cc) by Country, Spine Orthopedic Growth Factor Market, Europe, 2020 – 2030 |
Figure 8‑22: Units Sold (5 cc) by Country, Tibial Orthopedic Growth Factor Market, Europe, 2020 – 2030 |
Figure 8‑23: Leading Competitors by Country, Orthopedic Growth Factor Market, Europe, 2023 |
Figure 9‑1: Orthopedic Cell Therapy Market by Segment, Europe, 2020 – 2030 (€M) |
Figure 9‑2: Orthopedic Cell Therapy Market by Segment, Europe, 2020 – 2030 (US$M) |
Figure 9‑3: Platelet-Rich Plasma Market, Europe, 2020 – 2030 |
Figure 9‑4: Units Sold (10 cc) by Country, Platelet-Rich Plasma Market, Europe, 2020 – 2030 |
Figure 9‑5: Average Selling Price by Country, Platelet-Rich Plasma Market, Europe, 2020 – 2030 (€) |
Figure 9‑6: Average Selling Price by Country, Platelet-Rich Plasma Market, Europe, 2020 – 2030 (US$) |
Figure 9‑7: Market Value by Country, Platelet-Rich Plasma Market, Europe, 2020 – 2030 (€M) |
Figure 9‑8: Market Value by Country, Platelet-Rich Plasma Market, Europe, 2020 – 2030 (US$M) |
Figure 9‑9: Bone Marrow Aspirate Concentrate Market, Europe, 2020 – 2030 |
Figure 9‑10: Units Sold (10 cc) by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2020 – 2030 |
Figure 9‑11: Average Selling Price by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2020 – 2030 (€) |
Figure 9‑12: Average Selling Price by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2020 – 2030 (US$) |
Figure 9‑13: Market Value by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2020 – 2030 (€M) |
Figure 9‑14: Market Value by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2020 – 2030 (US$M) |
Figure 9‑15: Units Sold by Country, Soft-Tissue Platelet-Rich Plasma, Europe, 2020 – 2030 |
Figure 9‑16: Units Sold by Country, Spine Platelet-Rich Plasma, Europe, 2020 – 2030 |
Figure 9‑17: Units Sold by Country, Cardiac Platelet-Rich Plasma, Europe, 2020 – 2030 |
Figure 9‑18: Units Sold by Country, Orthopedic Platelet-Rich Plasma, Europe, 2020 – 2030 |
Figure 9‑19: Units Sold by Country, Plastics Platelet-Rich Plasma, Europe, 2020 – 2030 |
Figure 9‑20: Units Sold (10cc) by Country, Spine Bone Marrow Aspirate Concentrate Market, Europe, 2020 – 2030 |
Figure 9‑21: Units Sold (10cc) by Country, Soft-Tissue Bone Marrow Aspirate Concentrate Market, Europe, 2020 – 2030 |
Figure 9‑22: Units Sold (10 cc) by Country, Trauma Bone Marrow Aspirate Concentrate Market, Europe, 2020 – 2030 |
Figure 9‑23: Units Sold (10 cc) by Country, Joint Reconstruction Bone Marrow Aspirate Concentrate Market, Europe, 2020 – 2030 |
Figure 9‑24: Leading Competitors by Country, Orthopedic Cell Therapy Market, Europe, 2023 |
Figure 9‑25: Leading Competitors by Segment, Orthopedic Cell Therapy Market, Europe, 2023 |
Figure 9‑26: Leading Competitors by Country, Platelet-Rich Cell Therapy Market, Europe, 2023 |
Figure 9‑27: Leading Competitors by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2023 |
Figure 10‑1: Hyaluronic Acid Viscosupplementation Market by Segment, Europe, 2020 – 2030 (€M) |
Figure 10‑2: Hyaluronic Acid Viscosupplementation Market by Segment, Europe, 2020 – 2030 (US$M) |
Figure 10‑3: Total Hyaluronic Acid Viscosupplementation Market, Europe, 2020 – 2030 |
Figure 10‑4: Units Sold (Cycles) by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2020 – 2030 |
Figure 10‑5: Average Selling Price by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2020 – 2030 (€) |
Figure 10‑6: Average Selling Price by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2020 – 2030 (US$) |
Figure 10‑7: Market Value by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2020 – 2030 (€M) |
Figure 10‑8: Market Value by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2020 – 2030 (US$M) |
Figure 10‑9: Single-Injection Market, Europe, 2020 – 2030 |
Figure 10‑10: Units Sold (Cycles) by Country, Single-Injection Market, Europe, 2020 – 2030 |
Figure 10‑11: Average Selling Price by Country, Single-Injection Market, Europe, 2020 – 2030 (€) |
Figure 10‑12: Average Selling Price by Country, Single-Injection Market, Europe, 2020 – 2030 (US$) |
Figure 10‑13: Market Value by Country, Single-Injection Market, Europe, 2020 – 2030 (€M) |
Figure 10‑14: Market Value by Country, Single-Injection Market, Europe, 2020 – 2030 (US$M) |
Figure 10‑15: Two-Injection Market, Europe, 2020 – 2030 |
Figure 10‑16: Units Sold (Cycles) by Country, Two-Injection Market, Europe, 2020 – 2030 |
Figure 10‑17: Average Selling Price by Country, Two-Injection Market, Europe, 2020 – 2030 (€) |
Figure 10‑18: Average Selling Price by Country, Two-Injection Market, Europe, 2020 – 2030 (US$) |
Figure 10‑19: Market Value by Country, Two-Injection Market, Europe, 2020 – 2030 (€M) |
Figure 10‑20: Market Value by Country, Two-Injection Market, Europe, 2020 – 2030 (US$M) |
Figure 10‑21: Three-Injection Market, Europe, 2020 – 2030 |
Figure 10‑22: Units Sold (Cycles) by Country, Three-Injection Market, Europe, 2020 – 2030 |
Figure 10‑23: Average Selling Price by Country, Three-Injection Market, Europe, 2020 – 2030 (€) |
Figure 10‑24: Average Selling Price by Country, Three-Injection Market, Europe, 2020 – 2030 (US$) |
Figure 10‑25: Market Value by Country, Three-Injection Market, Europe, 2020 – 2030 (€M) |
Figure 10‑26: Market Value by Country, Three-Injection Market, Europe, 2020 – 2030 (US$M) |
Figure 10‑27: Five-Injection Market, Europe, 2020 – 2030 |
Figure 10‑28: Units Sold (Cycles) by Country, Five-Injection Market, Europe, 2020 – 2030 |
Figure 10‑29: Average Selling Price by Country, Five-Injection Market, Europe, 2020 – 2030 (€) |
Figure 10‑30: Average Selling Price by Country, Five-Injection Market, Europe, 2020 – 2030 (US$) |
Figure 10‑31: Market Value by Country, Five-Injection Market, Europe, 2020 – 2030 (€M) |
Figure 10‑32: Market Value by Country, Five-Injection Market, Europe, 2020 – 2030 (US$M) |
Figure 10‑33: Leading Competitors by Country, Hyaluronic Acid Viscosupplementation Market, Europe, 2023 |
Figure 11‑1: Orthopedic Cartilage Repair Market by Segment, Europe, 2020 – 2030 (€M) |
Figure 11‑2: Orthopedic Cartilage Repair Market by Segment, Europe, 2020 – 2030 (US$M) |
Figure 11‑3: Osteochondral Allograft Market, Europe, 2020 – 2030 |
Figure 11‑4: Units Sold by Country, Osteochondral Allograft Market, Europe, 2020 – 2030 |
Figure 11‑5: Average Selling Price by Country, Osteochondral Allograft Market, Europe, 2020 – 2030 (€) |
Figure 11‑6: Average Selling Price by Country, Osteochondral Allograft Market, Europe, 2020 – 2030 (US$) |
Figure 11‑7: Market Value by Country, Osteochondral Allograft Market, Europe, 2020 – 2030 (€M) |
Figure 11‑8: Market Value by Country, Osteochondral Allograft Market, Europe, 2020 – 2030 (US$M) |
Figure 11‑9: Meniscal Allograft Market, Europe, 2020 – 2030 |
Figure 11‑10: Units Sold by Country, Meniscal Allograft Market, Europe, 2020 – 2030 |
Figure 11‑11: Average Selling Price by Country, Meniscal Allograft Market, Europe, 2020 – 2030 (€) |
Figure 11‑12: Average Selling Price by Country, Meniscal Allograft Market, Europe, 2020 – 2030 (US$) |
Figure 11‑13: Market Value by Country, Meniscal Allograft Market, Europe, 2020 – 2030 (€M) |
Figure 11‑14: Market Value by Country, Meniscal Allograft Market, Europe, 2020 – 2030 (US$M) |
Figure 11‑15: Autologous Chondrocyte Implantation Market, Europe, 2020 – 2030 |
Figure 11‑16: Units Sold by Country, Autologous Chondrocyte Implantation Market, Europe, 2020 – 2030 |
Figure 11‑17: Average Selling Price by Country, Autologous Chondrocyte Implantation Market, Europe, 2020 – 2030 (€) |
Figure 11‑18: Average Selling Price by Country, Autologous Chondrocyte Implantation Market, Europe, 2020 – 2030 (US$) |
Figure 11‑19: Market Value by Country, Autologous Chondrocyte Implantation Market, Europe, 2020 – 2030 (€M) |
Figure 11‑20: Market Value by Country, Autologous Chondrocyte Implantation Market, Europe, 2020 – 2030 (US$M) |
Figure 11‑21: Osteochondral Autograft Market, Europe, 2020 – 2030 |
Figure 11‑22: Units Sold by Country, Osteochondral Autograft Market, Europe, 2020 – 2030 |
Figure 11‑23: Average Selling Price by Country, Osteochondral Autograft Market, Europe, 2020 – 2030 (€) |
Figure 11‑24: Average Selling Price by Country, Osteochondral Autograft Market, Europe, 2020 – 2030 (US$) |
Figure 11‑25: Market Value by Country, Osteochondral Autograft Market, Europe, 2020 – 2030 (€M) |
Figure 11‑26: Market Value by Country, Osteochondral Autograft Market, Europe, 2020 – 2030 (US$M) |
Figure 11‑27: Leading Competitors, Orthopedic Cartilage Repair Market, Europe, 2023 |